Strategic Partnerships 小 OncoOne is actively engaging with external experts by expanding its Scientific Advisory Board and pursuing high-profile radioligand therapy conferences, signaling openness to collaborations, co-development, and potential strategic partnerships with bigger biotech players or contract research organizations.

Clinical & Academic Outreach OncoOne’s presence at conferences and its radiotheranostics platform positioning present multiple entry points for collaborative research agreements, joint feasibility studies, or sponsored research with academic medical centers and hospitals seeking novel radiopharmaceuticals.

Early-Stage Focus With a small team and funding of modest scale, the company looks like an ideal partner for milestone-based deals, CDMO collaborations, or licensing agreements to commercialize its PreTarg-it platform and lead candidates in early-stage oncology indications.

Radiotheranostics Demand The focus on radiotheranostics and oxMIF-targeting antibodies positions OncoOne to engage pharma customers seeking precision radiopharmaceuticals, companion diagnostics co-development, or radioligand therapy programs in solid tumor indications.

Financial Levers With revenue under one million and a $14M funding runway, there is motivation to pursue co-development funding, grant-backed programs, or strategic investments from larger biotechs looking to augment their oncology portfolio with innovative radiopharmaceutical platforms.